Best Food to Eat on Retatrutide: A UK Clinical Guide

The best food to eat on retatrutide supports tolerance, nutritional balance, and digestive comfort during a treatment that significantly slows gastric emptying and reduces appetite. Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently available only through authorised clinical trials in the UK. Because it alters how the digestive system processes food, dietary choices become especially important for managing side effects and maintaining adequate nutrition. This guide covers which foods to prioritise, what to avoid, practical meal planning strategies, and how to stay well hydrated throughout treatment.

How Retatrutide Affects Appetite and Digestion

Retatrutide activates GLP-1, GIP, and glucagon receptors, slowing gastric emptying and reducing appetite, which can cause nausea, bloating, and prolonged fullness, particularly during dose escalation.

Retatrutide is an investigational triple agonist that targets three incretin and metabolic receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.^[1][2] In a Phase 2 trial published in the New England Journal of Medicine (2023), it demonstrated substantial weight loss in adults with obesity; that trial also established the once-weekly subcutaneous injection regimen, though individual trial protocols may differ.^[1][2] As of mid-2025, retatrutide has not received approval from the MHRA or EMA and remains under clinical investigation (ClinicalTrials.^[8]gov identifier: NCT05929066). This page will be reviewed periodically to reflect any change in regulatory status. Retatrutide should only be taken by people enrolled in an authorised clinical trial, under the supervision of a qualified clinician. Obtaining unlicensed or compounded versions outside a trial is not recommended.

By activating GLP-1 receptors, retatrutide slows gastric emptying — the rate at which food moves from the stomach into the small intestine.^[9][10] This delay is a key reason why people taking retatrutide feel full more quickly and for longer after eating. It can also lead to symptoms such as nausea, bloating, and a prolonged sensation of fullness, particularly during the dose-escalation phase. The degree of gastric slowing tends to be greatest in the early weeks of treatment and may attenuate with continued use.

The glucagon receptor component may contribute to increased energy expenditure and fat metabolism, though the human evidence for this effect is still evolving and should not be overstated. Together, these mechanisms produce a meaningful reduction in appetite and caloric intake.

For people taking retatrutide in a clinical trial, eating habits will need to adapt — not simply because of reduced hunger, but because the digestive system is operating under different physiological conditions. Slowed gastric emptying can affect the absorption of some oral medicines, particularly those with a narrow therapeutic index (for example, certain thyroid medications or anticoagulants). There is also UK regulatory precedent, based on the tirzepatide (Mounjaro) Summary of Product Characteristics, for reduced exposure of oral contraceptives during initiation or dose escalation of related incretin-based therapies; people using oral contraceptives should raise this with their prescriber or trial team. Anyone taking medicines that may be affected should discuss this before starting treatment.

Foods That Support Tolerance and Nutritional Balance

Lean proteins, easily digestible carbohydrates such as boiled potato and soft-cooked vegetables, and modest amounts of healthy fats form the most appropriate dietary foundation during retatrutide treatment.

Given the slowed gastric emptying associated with retatrutide, choosing foods that are gentle on the digestive system while remaining nutrient-dense is a clinical priority. The goal is to maintain adequate intake of protein, micronutrients, and fibre without overwhelming a digestive tract that is already processing food more slowly than usual.

Protein-rich foods should form the cornerstone of the diet. Lean sources such as chicken breast, turkey, eggs, low-fat dairy (for example, Greek yoghurt or cottage cheese), white fish, and legumes help preserve muscle mass during weight loss — a particular concern when caloric intake is substantially reduced. Aim to include a source of protein at every meal, even if portions are small. People with chronic kidney disease or frailty may have specific protein requirements and should discuss individual targets with a registered dietitian.

Easily digestible carbohydrates are often preferable during the initial adjustment period, as individual tolerance to higher-fibre options can vary. Options that many people find well tolerated include:

• Boiled or mashed potato (without heavy cream or butter)

• White rice or plain pasta in small quantities

• Soft-cooked vegetables such as courgette, carrots, and spinach

Porridge oats are nutritious but contain moderate fibre; introduce them gradually and according to individual tolerance. As overall tolerance improves, transitioning towards higher-fibre whole grains — such as wholemeal bread, brown rice, and lentils — supports gut health and helps regulate blood glucose levels. The NHS Eatwell Guide (www.nhs.uk/live-well/eat-well/the-eatwell-guide) and Diabetes UK (www.diabetes.org.uk/guide-to-diabetes/enjoy-food/carbohydrates-and-diabetes) provide practical, evidence-based advice on balanced carbohydrate choices.

Healthy fats from sources such as avocado, olive oil, and oily fish (salmon, mackerel) provide essential fatty acids and fat-soluble vitamins. However, high-fat meals should be kept modest in size, as fat slows gastric emptying further and may worsen nausea.

A registered dietitian can provide personalised guidance to ensure nutritional adequacy throughout treatment, in line with NICE guidance on obesity management (NG246).

What to Avoid Eating While Taking Retatrutide

High-fat and fried foods, sugary and ultra-processed foods, large portions, alcohol, and carbonated beverages should be avoided or minimised as they worsen gastrointestinal side effects and destabilise blood glucose.

Certain foods are more likely to exacerbate the gastrointestinal side effects associated with retatrutide, particularly during the dose-escalation phase when the body is still adjusting to the medication. Being mindful of these dietary triggers can meaningfully improve day-to-day comfort and adherence to treatment.

High-fat and fried foods are among the most problematic. Foods such as chips, pastries, full-fat takeaways, and heavily buttered dishes slow gastric emptying even further, compounding the drug's existing effect and increasing the risk of nausea, vomiting, and upper abdominal discomfort. These should be minimised or avoided, particularly in the early weeks of treatment.

Sugary and ultra-processed foods — including fizzy drinks, sweets, cakes, and highly refined snacks — offer little nutritional value and can cause rapid fluctuations in blood glucose. The Phase 2 trial (NEJM, 2023) demonstrated glucose-lowering effects with retatrutide; maintaining stable blood sugar through dietary choices is therefore an important complementary strategy.^[4][1] Diabetes UK provides helpful guidance on free sugars and ultra-processed foods for people managing blood glucose (www.diabetes.org.uk/guide-to-diabetes/enjoy-food/eating-with-diabetes/whats-your-poison/sugar).

Other foods and habits to be mindful of include:

• Large portion sizes — even of healthy foods, as the stomach empties slowly and overeating can cause significant discomfort

• Spicy foods — evidence is limited, but some people find these worsen gastrointestinal symptoms; avoid them if they trigger or aggravate your symptoms

• Alcohol — can worsen nausea, impair blood glucose regulation, and interact with the metabolic effects of the drug. The NHS advises drinking no more than 14 units of alcohol per week, spread over three or more days, with several alcohol-free days each week.^[19][20] People taking retatrutide alongside insulin or sulfonylureas should be particularly cautious, as alcohol can increase the risk of hypoglycaemia; discuss glucose monitoring with your prescriber

• Carbonated beverages — contribute to bloating and gas

Individual tolerances vary. Keeping a simple food diary can help identify personal triggers and support more informed conversations with a GP, dietitian, or trial clinician.

Practical Meal Planning Tips for People Taking Retatrutide

Eating four to five small, nutrient-dense meals spread throughout the day is better tolerated than three large meals, and every portion should prioritise protein to support muscle preservation.

Adapting meal planning to the realities of reduced appetite and altered digestion is one of the most practical steps a person can take to support their health whilst taking retatrutide. Rather than following conventional three-meal-a-day patterns, many people find that smaller, more frequent meals — for example, four to five modest portions spread throughout the day — are far better tolerated and help maintain consistent energy levels. Based on the Phase 2 trial regimen (NEJM, 2023), retatrutide is administered as a weekly injection, though individual trial protocols may differ; meals do not need to be timed around the injection itself.^[3] Focus instead on eating smaller amounts when you feel able to, guided by your symptoms and your trial team's advice.

Prioritise nutrient density over volume. Because overall food intake is likely to be lower, every meal and snack should work hard nutritionally. A small bowl of Greek yoghurt with berries and a handful of nuts, for instance, delivers protein, healthy fats, antioxidants, and calcium in a compact, easily digestible format.

Some practical planning strategies include:

• Preparing meals in advance to avoid reaching for convenience foods when appetite is low or unpredictable

• Eating slowly and mindfully, chewing thoroughly to ease the digestive burden

• Stopping eating at the first sign of fullness — slowed gastric emptying means satiety signals may arrive more abruptly than expected

• Including a source of protein at every meal to support muscle preservation

For people managing retatrutide alongside type 2 diabetes, particularly those also taking insulin or sulfonylureas, there is an increased risk of hypoglycaemia as food intake decreases. Blood glucose should be monitored closely and a medication review sought from your GP or diabetes specialist (see NICE NG28: Type 2 diabetes in adults: management).

When to seek help — red flags: Contact your GP or trial clinician promptly if you experience persistent or worsening nausea and vomiting, are unable to keep fluids down for more than 24 hours, or notice significant unintentional weight loss or difficulty maintaining adequate nutrition. Seek urgent medical attention (call NHS 111 or 999 in an emergency) if you develop severe abdominal pain — especially pain that radiates to the back (which may indicate pancreatitis) — or right upper quadrant pain with fever or jaundice (which may indicate gallbladder disease). These are recognised class effects associated with GLP-1-based therapies. A referral to a registered dietitian is strongly advisable if nutritional intake is a concern, consistent with NICE guidance on obesity management (NG246).

Staying Hydrated and Managing Common Side Effects

Sipping 6 to 8 cups of fluid daily, primarily water, and eating cold or room-temperature foods can help manage nausea and prevent dehydration caused by vomiting or diarrhoea.

Adequate hydration is particularly important for people taking retatrutide, as nausea and vomiting — the most commonly reported gastrointestinal side effects in clinical trials — can lead to fluid and electrolyte losses. The NHS recommends around 6 to 8 cups or glasses of fluid per day for most adults, with water, lower-fat milk, and sugar-free drinks all counting towards this total.^[22][23] This guidance remains relevant, if not more so, during treatment with agents that affect the gastrointestinal tract.

Water should be the primary fluid of choice. Herbal teas, diluted fruit juice, and clear broths are also well tolerated by most people. Sipping fluids steadily throughout the day, rather than drinking large amounts at once, is generally better tolerated when gastric emptying is delayed. Avoid drinking large quantities of fluid immediately before or during meals, as this can contribute to uncomfortable fullness.

For managing nausea specifically, the following strategies may help:

• Eating cold or room-temperature foods, which tend to have less aroma and are often better tolerated than hot meals

• Ginger-based foods or drinks (for example, ginger tea or ginger biscuits) — there is modest evidence supporting ginger's role in reducing nausea^[24][25]

• Resting upright for 30 to 60 minutes after eating to support gastric transit

• Avoiding strong food smells during preparation if nausea is prominent

Constipation is another common side effect associated with GLP-1-based therapies.^[28] Gradually reintroducing dietary fibre as tolerated, maintaining adequate fluid intake, and staying physically active can all help. The NHS provides self-care guidance on constipation at www.nhs.uk/conditions/constipation. If constipation is persistent, discuss the use of a suitable laxative with your clinician before starting one.

Diarrhoea may also occur, particularly in the early weeks. If diarrhoea is significant, oral rehydration solutions (available from pharmacies) can help replace lost fluids and electrolytes. The NHS provides guidance on managing diarrhoea and vomiting at www.nhs.uk/conditions/diarrhoea-and-vomiting. Seek advice from your GP or trial clinician if diarrhoea is severe or prolonged.

If any side effects are severe, persistent, or significantly affecting quality of life or nutritional intake, contact your GP or prescribing clinician promptly. Dose adjustment or a temporary pause in treatment may be considered. Do not attempt to self-manage serious symptoms without professional guidance.

As retatrutide remains an investigational medicine without full regulatory approval in the UK, any suspected side effects should be reported to your trial team. Outside of a trial setting, suspected side effects of a medicine can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Frequently Asked Questions